Tuesday, June 29, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

Video Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Chronic Lymphocytic Leukemia and Follicular Lymphoma

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Tuesday, June 29th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Nathan H Fowler, MD
Professor, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Prof John G Gribben, MD, DSc, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Queen Mary University of London
Charterhouse Square
London, United Kingdom

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seagen Inc, and Takeda Oncology.

Chronic Lymphocytic Leukemia (CLL)

  • Clinical and biologic factors in the selection of first-line treatment for patients with newly diagnosed CLL
  • Impact of various patient-related factors (eg, hypertension, chronic kidney disease, need for anticoagulation, compliance concerns, treatment for gastroesophageal reflux disease) on front-line decision-making
  • Optimal utilization of ibrutinib-based regimens as front-line therapy for younger and older patients with treatment-naïve CLL
  • Evidence-based incorporation of acalabrutinib into first-line and relapsed/refractory (R/R) CLL treatment algorithms
  • Efficacy and safety findings with and current clinical role of limited-duration therapy with venetoclax-based regimens for treatment-naïve and R/R CLL
  • Pharmacologic similarities and differences among ibrutinib, acalabrutinib and zanubrutinib; available data with and potential role of zanubrutinib in CLL management
  • Selection and sequencing of therapy for patients who experience disease relapse on first-line Bruton tyrosine kinase (BTK) or Bcl-2 inhibition
  • Current use of the PI3 kinase inhibitors idelalisib and duvelisib in the CLL treatment paradigm
  • Biologic rationale for the evaluation of and clinical research findings with CD19-directed CAR (chimeric antigen receptor) T-cell therapy for patients with R/R CLL
  • Mechanisms of action, available data and ongoing evaluation of novel noncovalent reversible BTK inhibitors for patients with R/R CLL; potential role in CLL management
  • Available efficacy and safety outcomes from studies evaluating combinations of novel BTK/Bcl-2 inhibitors for previously untreated and R/R CLL; ongoing Phase III studies

Follicular Lymphoma (FL)

  • Evidence-based selection of induction therapy for patients with newly diagnosed FL
  • Integration of obinutuzumab into current algorithms for treatment-naïve and R/R FL; potential benefit in preventing early disease progression
  • Key factors in the selection and sequencing of therapy for patients with R/R FL; optimal integration of lenalidomide/rituximab
  • Current clinical role and patient selection for PI3 kinase inhibition in FL
  • Design, eligibility criteria and emerging efficacy findings from the Phase III CHRONOS-3 trial evaluating copanlisib in combination with rituximab for patients with R/R FL; implications for clinical practice
  • Incidence of EZH2 mutations in patients with FL; mechanism of action of tazemetostat in EZH2-mutated and wild-type FL
  • Key efficacy and tolerability findings with tazemetostat for patients with previously treated FL with and without EZH2 mutations; optimal integration into practice
  • Mechanism of action, available data and recent FDA approval of umbralisib for patients with R/R FL
  • Available data from the Phase II ZUMA-5 study illustrating the efficacy of axicabtagene ciloleucel in patients with indolent lymphomas; recent FDA approval and current clinical role of axicabtagene ciloleucel in FL treatment
  • Design, eligibility criteria and emerging results from the pivotal Phase II ELARA study evaluating tisagenlecleucel for patients with R/R FL; FDA regenerative medicine advanced therapy designation and developmental timeline for tisagenlecleucel in FL
  • Mechanism of action, available data, FDA breakthrough therapy designation and ongoing evaluation of mosunetuzumab for R/R FL

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

Learning Objectives

  • Individualize the selection and sequencing of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), considering clinical presentation, age, performance status, biomarker profile and coexisting medical conditions.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to discern how this strategy can be optimally integrated into nonresearch treatment.
  • Appraise the Phase III data supporting the recent FDA approval of acalabrutinib for newly diagnosed or previously treated CLL, and identify patients for whom treatment with this agent may be appropriate.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how to appropriately integrate this regimen into treatment decision-making.
  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
  • Appreciate the FDA approval of rituximab/lenalidomide for the management of R/R FL and available Phase III data investigating this regimen as front-line therapy, and optimally incorporate this novel therapeutic approach into treatment algorithms.
  • Recognize the recent FDA approval of tazemetostat for R/R FL, and identify patients for whom treatment with this novel agent may be appropriate.
  • Review available efficacy and safety data with CAR (chimeric antigen receptor) T-cell therapies, and identify patients with R/R FL or R/R CLL for whom this approach may be appropriate.
  • Assess the ongoing clinical trials evaluating other novel investigational approaches for FL and CLL, and obtain consent from appropriate patients for study participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seagen Inc, and Takeda Oncology.